Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
GB-2064 by Galecto for Myelofibrosis: Likelihood of Approval
GB-2064 is under clinical development by Galecto and currently in Phase II for Myelofibrosis. According to GlobalData, Phase II drugs...
GB-2064 by Galecto for Post-Polycythemia Vera Myelofibrosis (PPV-MF): Likelihood of Approval
GB-2064 is under clinical development by Galecto and currently in Phase II for Post-Polycythemia Vera Myelofibrosis (PPV-MF). According to GlobalData,...
GB-2064 by Galecto for Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF): Likelihood of Approval
GB-2064 is under clinical development by Galecto and currently in Phase II for Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF). According to...